| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g | |||
| Other Sizes |
Purity: ≥98%
Warfarin sodium (trade names Coumadin among others) is an anticoagulant normally used in the prevention of thrombosis and thromboembolism, the formation of blood clots in the blood vessels and their migration elsewhere in the body, respectively. It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism and to prevent stroke in people who have atrial fibrillation, valvular heart disease or artificial heart valves. Less commonly it is used following ST-segment elevation myocardial infarction and orthopedic surgery. It is generally taken by mouth but may also be used by injection into a vein. Warfarin was initially introduced in 1948 as a pesticide against rats and mice, and is still used for this purpose, although more potent poisons such as brodifacoum have since been developed. In the early 1950s, warfarin was found to be effective and relatively safe for preventing thrombosis and thromboembolism in many disorders. It was approved for use as a medication in 1954, and has remained popular ever since. Warfarin is the most widely prescribed oral anticoagulant drug in North America.
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Warfarin Use During Lactation Because the concentration of warfarin in breast milk is extremely low when the daily dose is at least 12 mg, the amount ingested by the infant is very small. Even when the mother takes 25 mg daily for 7 days during lactation, no adverse reactions have been reported in breastfed infants. It is generally believed that the risk to breastfed infants from mothers receiving warfarin treatment during lactation is minimal, and no special precautions are necessary. The postpartum warfarin dose required by women may need to be up to twice that before pregnancy. Whether breastfeeding leads to an increased need for vitamin K is unclear. ◉ Effects on Breastfed Infants Two infants, breastfed for 56 days and 131 days respectively, did not experience a decrease in vitamin K-dependent clotting factor levels or bleeding during their mothers' warfarin anticoagulation therapy. In a telephone follow-up study, mothers taking warfarin reported no adverse reactions in their five breastfed infants. A mother was taking 5 mg warfarin daily for the first 7 weeks postpartum due to a pulmonary embolism. She mistakenly ingested a dose of 25 mg/day and continued this for 7 days. Upon presentation to the emergency room, her international normalized ratio (INR) was greater than 10 (the usual therapeutic upper limit is 3.5), prothrombin time was greater than 100 seconds (normal value not exceeding 11.2 seconds), and activated partial thromboplastin time (aPTT) was 62.5 seconds (normal value not exceeding 32.7 seconds). She had been exclusively breastfeeding her infant almost exclusively since birth. Her 8-week-old infant was in good health with an INR of 1.0, a prothrombin time of 10.3 seconds, and a slightly elevated aPTT of 33.8 seconds. However, 3 weeks prior, the infant's aPTT was 38.9 seconds, therefore the elevated aPTT was not determined to be caused by warfarin. ◉ Effects on breastfeeding and lactation As of the revision date, no relevant published information was found. |
|---|---|
| References |
http://en.wikipedia.org/wiki/Warfarin
|
| Additional Infomation |
Warfarin sodium is a slightly bitter-tasting crystalline powder and an anticoagulant used as a rodenticide. (EPA, 1998)
Warfarin sodium is the sodium salt of warfarin, a coumarin compound and a vitamin K antagonist with anticoagulant activity. Warfarin sodium inhibits vitamin K and vitamin K epoxide reductase, thereby interfering with the cyclic conversion of vitamin K epoxide with its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of N-terminal glutamate residues in vitamin K-dependent proteins. Therefore, the maturation of vitamin K-dependent coagulation factors II, VII, IX, and X, as well as anticoagulant proteins C and S, is inhibited. The lack of these coagulation factors prevents thrombosis and clot formation. An anticoagulant that works by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prevention and/or treatment of venous thrombosis and its spread, pulmonary embolism, and atrial fibrillation with embolism. It can also be used as an adjunct drug for the prevention of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. See also: Warfarin (containing the active ingredient). |
| Molecular Formula |
C19H15NAO4
|
|---|---|
| Molecular Weight |
330.31477
|
| Exact Mass |
330.086
|
| CAS # |
129-06-6
|
| Related CAS # |
129-06-6 (sodium);81-81-2 (free acid);2610-86-8 (potassium);
|
| PubChem CID |
16204922
|
| Appearance |
Solid Powder
|
| Density |
1.307g/cm3
|
| Boiling Point |
515.2ºC at 760mmHg
|
| Flash Point |
188.8ºC
|
| LogP |
4.047
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
508
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+]
|
| InChi Key |
KYITYFHKDODNCQ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C19H16O4.Na/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3/q+1/p-1
|
| Chemical Name |
sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate
|
| Synonyms |
Coumadin, Aldocumar, Tedicumar, Warfant, Marevan
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0275 mL | 15.1373 mL | 30.2746 mL | |
| 5 mM | 0.6055 mL | 3.0275 mL | 6.0549 mL | |
| 10 mM | 0.3027 mL | 1.5137 mL | 3.0275 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA